The increased plasma cell numbers in the blood, observed mainly in the 0.6 mg QD dose group, might be driven by an increased production of IL-2 and IL-10, which can act as plasma cell differentiation factors.20 This observed increase in plasma cells, combined with the upward trend in CD8+ T cells, suggests that the 0.6 mg QD iberdomide dose may result in undesirable pharmacodynamic effects in the context of lupus treatment. Here, IL10 is linked to systemic lupus erythematosus.